<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26692">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01848015</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG5003</org_study_id>
    <nct_id>NCT01848015</nct_id>
  </id_info>
  <brief_title>Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer</brief_title>
  <official_title>Prediction of Recurrence in Advanced Gastric Cancer After Radical Resection by Circulating Tumor Cells （CTCs）</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the predictive value of circulating tumor cells (CTCs) for recurrence of advanced
      gastric cancer after radical resection.

      To identify the relationship between the detection of circulation tumor cells and recurrence
      patterns of gastric cancer after radical resection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>CTCs</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of gastric cancer after radical resection</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>CTCs positive</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>detection of CTCs</intervention_name>
    <arm_group_label>CTCs positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients with advanced gastric cancer accepted radical resection(D2)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having signed informed consent

          -  Age≥ 18 years old

          -  Histologically confirmed gastric adenocarcinoma

          -  Preoperative clinical examination and imaging indicating operable disease

          -  complete resection (R0 resection)

          -  D2 or D2+ resection

        Exclusion Criteria:

          -  Other tumor type than adenocarcinoma

          -  Patients who have been given preoperative chemotherapy/chemoradiation.

          -  Staging investigations or intraoperative exploration indicating inoperable disease

          -  R1 or R2 resection

          -  D0 or D1 resection

          -  Patients unreliable for follow up

          -  Past history of malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, MD,PhD</last_name>
    <phone>(86)10-88196175</phone>
    <email>lin100@medmail.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking cancer hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ming Lu, MD</last_name>
      <phone>(86)10-88196561</phone>
      <email>qiminglu_mail@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 27, 2013</lastchanged_date>
  <firstreceived_date>May 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Director of GI oncology</investigator_title>
  </responsible_party>
  <keyword>CTCs before and after gastrectomy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
